Publisher Correction: Circulating serum HBsAg level is a biomarker for HBV-specific T and B cell responses in chronic hepatitis B patients.

An amendment to this paper has been published and can be accessed via a link at the top of the paper.

Correction to: Scientific Reports 10.1038/s41598-020-58870-2, published online 04 February 2020

Supplementary Tables 1 and 2 are omitted from the Supplementary Information which accompanies this Article. Tables S1 and S2 appear below.

Table S1

Demographic details of cohorts of HBslo and HBshi CHB patients and healthy subjects.

	CHB (HBslo)	CHB (HBshi)	healthy donors (HD)
Serum HBsAg levels (IU/ml)	<500	<50,000	N/A
number of subjects	23	16	10
median age (years) (range)	54 (31–80)	35 (26–60)	37 (63–27)
Gender (M/F)	20/3	12/4	6/4
Ethnicity (Asian/African/Caucasian)	15/5/3	5/11/0	2/0/8
HBV DNA (log IU/ml) (mean ± SD)	2.07 ± 1.04	4.43 ± 2.36	N/A
HBeAg (-ve/+ve/UA)	20/2/1	12/4/0	N/A
anti-HBeAb (-ve/+ve/UA)	5/14/4	5/6/5	N/A
median ALT (U/L) (range)	31.0 (9.0–542.0)	41.0 (14.0–536.0)	N/A
median AST (U/L) (range)	26.0 (15.0–430.0)	39.5 (17.0–259.0)	N/A

SD: standard deviation, UA: Unavailable, ALT: alanine transaminase, AST: aspartate transaminase, N/A: Not applicable.

Table S2

Details of subjects in second cohort of CHB patients.

	CHBHBsAg <100 IU/ml	CHBHBsAg >5,000 IU/ml
number of subjects	23	8
median age (years) (range)	52 (34–71)	52 (39–72)
Gender (M/F)	15/8	4/4
HBeAg (-ve/+ve/UA)	14/1/8	1/1/6

UA: Unavailable.